DUBAI: The United Arab Emirates has suspended all incoming flights from India due to a surge in coronavirus infections there, the UAE’s National Emergency Crisis and Disaster Management Authority (NCEMA) said on Thursday.
Flights transiting through the UAE on the way to India will continue, NCEMA said on Twitter.
India recorded the world's highest daily tally of 314,835 new COVID-19 infections on Thursday as a second wave of the pandemic raised new fears about the ability of crumbling health services to cope.
Health officials across northern and western India including the capital, New Delhi, said they were in crisis, with most hospitals full and running out of oxygen.

CAIRO: Two agreements have been signed between the Egyptian Holding Company for Biological Products and Vaccines (Vacsera), and the Chinese company Sinovac Biotech for biopharmaceuticals, to manufacture the coronavirus vaccine in Egypt.
The signing of the agreements comes as part of efforts to achieve technical cooperation in this vital field.
The plan is to take advantage of the vaccine developed by the Chinese company Sinovac, a leader in research, development, production and marketing in pharmaceutical preparations, and exchange experiences to support Vacsera, a specialist in the manufacture of vaccines in Egypt.
The move is expected to contribute to limiting the spread of the virus.
Both agreements were signed by Heba Wali, Vacsera head and Sinovac Biotech vice president.
The first agreement concerns the manufacturing technology for the coronavirus vaccine, Egyptian Health Minister Hala Zayed said.
Under this deal, the Chinese company Sinovac gives Vacsera a limited license to use manufacturing technology and technical knowledge for the purpose of manufacturing the local final product of the COVID-19 vaccine, in Vecsera’s manufacturing sites inside Egypt — using the ready-made product of the vaccine provided by Sinovac.
This agreement also stipulates that the Chinese company will provide Vacsera with all technical information related to the vaccine and provide technical assistance.
It includes examining the manufacturing places of Vacsera, and manufacturing the local final product using the ready-made product provided by Sinovac.
This is in addition to testing the local end-product, manufacturing methods and technical processes used, as well as equipment, tools or machines, repair and maintenance of Vacsera’s manufacturing facilities.
Quality management and quality control are also part of this process.
The second agreement relates to the local manufacture of the COVID-19 vaccine, Zayed said.
It provides for the Chinese company, Sinovac, to grant a permit to Vacsera to refill, package and manufacture the local final product of the COVID-19 vaccine in Vacsera’s own facilities.
It provides for Vacsera obtaining regulatory approvals, manufacturing technology and technical knowledge for the use of the ready-to-fill product provided by Sinovac, Zayed added.
The agreement stipulates that Vacsera will equip its current facilities or construct, build and equip new facilities to serve as manufacturing facilities.
An effective quality-management system will be set up for each step of production.
It enables the local manufacturer to meet the requirements, specifications and standards of operating procedures of Sinovac.
Sinovac will provide technical support and assistance to Vacsera in building and equipping manufacturing facilities to meet the required standards.
The agreement also stipulates that Sinovac is ready, at the request of Vacsera, to provide the necessary training for Vacsera employees in manufacturing facilities in Egypt or at its own facilities in Beijing, regarding final packaging and final quality-control operations.